Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
LUFYLLIN vs ELIXICON
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
LUFYLLIN (dyphylline) is a xanthine bronchodilator that inhibits phosphodiesterase, increasing intracellular c AMP levels, leading to relaxation of bronchial smooth muscle and suppression of airway hyperresponsiveness. It also antagonizes adenosine receptors.
Theophylline is a xanthine derivative that inhibits phosphodiesterase, leading to increased intracellular cyclic AMP levels. It also acts as a nonselective adenosine receptor antagonist, resulting in bronchodilation and anti-inflammatory effects.
FDA-approved: Relief and prevention of bronchospasm associated with asthma, chronic bronchitis, and emphysema.,Off-label: Apnea of prematurity, COPD exacerbations.
Treatment of symptoms and reversible airflow obstruction associated with chronic asthma,Management of chronic obstructive pulmonary disease (COPD),Off-label: Apnea of prematurity
200-400 mg orally 3-4 times daily, not to exceed 1600 mg/day. Also available as 200 mg/m L injection, administer 200-400 mg IM or slow IV every 6-8 hours.
400 mg orally every 6 hours or 600 mg orally every 8 hours; extended-release: 600-1200 mg orally every 12 hours.
6-8 hours in adults with normal hepatic and renal function. In neonates, half-life is prolonged to 20-30 hours. In patients with hepatic cirrhosis, half-life may extend to 20-30 hours. In congestive heart failure, half-life is prolonged to 12-20 hours.
Terminal elimination half-life: 4-6 hours in adults; 3-4 hours in children; prolonged in hepatic impairment or congestive heart failure. Context: dosing interval adjustment required in these conditions.
Dyphylline is not metabolized by the liver; it is primarily excreted unchanged by the kidneys. Approximately 80% is eliminated unchanged in urine.
Primarily hepatic metabolism via cytochrome P450 1A2 (CYP1A2). Minor pathways include CYP2E1 and CYP3A4. Metabolites are excreted renally.
Primarily renal excretion of unchanged drug and metabolites. Approximately 50% is excreted unchanged in urine, with the remainder as metabolites (including 7-hydroxypropyltheophylline and 1,3-dimethyluric acid). Biliary/fecal elimination accounts for <10%.
Renal: 50% unchanged; hepatic metabolism to 3-methylxanthine, theophylline, etc. Biliary/fecal: minimal.
Approximately 40-50% bound to plasma proteins, primarily albumin.
Approximately 40% bound, primarily to albumin.
0.5-0.7 L/kg. This indicates distribution into total body water with some tissue binding.
Vd: 0.3-0.5 L/kg; indicates distribution into total body water, minimal tissue binding.
Oral immediate-release: 90-100%. Rectal: approximately 80-90%. Sustained-release: 70-90% with delayed absorption.
Oral immediate-release: 100%; Extended-release: 100% (well-absorbed, no first-pass metabolism).
Cr Cl 30-50 m L/min: administer 50-75% of normal dose. Cr Cl <30 m L/min: administer 25-50% of normal dose. Consider monitoring theophylline levels.
GFR > 50 m L/min: no adjustment; GFR 10-50 m L/min: reduce dose by 25-50% and monitor theophylline levels; GFR < 10 m L/min: reduce dose by 50% and monitor levels.
Child-Pugh A: no adjustment. Child-Pugh B: administer 50% of normal dose. Child-Pugh C: avoid use or administer 25% of normal dose with close monitoring.
Child-Pugh Class A: no adjustment; Child-Pugh Class B: reduce dose by 50%; Child-Pugh Class C: reduce dose by 75% and monitor levels.
Children <1 year: 100-200 mg/day in 3-4 divided doses. Children 1-9 years: 200-300 mg/day in 3-4 divided doses. Children 9-16 years: 200-400 mg/day in 3-4 divided doses. Weight-based alternative: 10-20 mg/kg/day in 3-4 divided doses.
Initial: 5 mg/kg/dose orally every 6 hours; maintenance: 100-400 mg/day in divided doses; monitor levels aggressively.
Initiate at lower end of dosing range (200 mg 3 times daily). Monitor theophylline levels and adjust dose to maintain trough concentration of 5-15 mcg/m L. Reduce dose if concurrent medications affecting hepatic metabolism.
Start at lowest effective dose (e.g., 200 mg orally every 12 hours) due to reduced clearance; monitor theophylline levels and adjust based on response and tolerability.
No FDA black box warning.
Theophylline has a narrow therapeutic index; plasma levels should be monitored to avoid toxicity. Dosage should be individualized based on steady-state serum concentrations. Concurrent illness, fever, or changes in smoking habits can alter theophylline clearance.
Use with caution in patients with peptic ulcer disease, hyperthyroidism, hypertension, cardiac arrhythmias, or seizure disorders. Monitor serum levels for toxicity. Risk of ventricular arrhythmias or seizures at high doses.
Risk of seizures at high serum levels; may induce or worsen arrhythmias; use with caution in patients with peptic ulcer disease, hyperthyroidism, or seizure disorders; drug interactions with cimetidine, fluoroquinolones, macrolides, and allopurinol can increase theophylline levels.
Hypersensitivity to dyphylline or any xanthine derivative. Uncontrolled arrhythmias. Active seizure disorder. Severe hypotension. Concurrent use with other xanthines (e.g., theophylline).
Hypersensitivity to theophylline or any component of the formulation; pre-existing cardiac arrhythmias (e.g., tachyarrhythmias); active seizure disorder.
Avoid large amounts of caffeine-containing foods and beverages (coffee, tea, cola, chocolate) as they may increase adverse effects like nervousness and palpitations. No significant food interactions other than caffeine. Alcohol may increase CNS stimulation.
Avoid large amounts of caffeine-containing foods and beverages such as coffee, tea, cola, and chocolate as they may increase side effects like jitteriness and insomnia. High-fat meals may affect absorption; take consistently with respect to meals. Charcoal-broiled foods may increase metabolism of theophylline, reducing efficacy.
Lufyllin (dyphylline) is a xanthine derivative bronchodilator. Animal studies have not demonstrated teratogenicity. Human data are limited; however, as a methylxanthine, risks are considered low. First trimester: No evidence of major malformations. Second and third trimesters: No known fetal harm, but high doses may cause transient neonatal tachycardia or irritability due to placental transfer. Avoid use near term if possible due to potential neonatal effects.
Insufficient human data; animal studies show fetal toxicity at high doses. Avoid in first trimester unless benefit outweighs risk. Second and third trimester: use only if clearly needed.
Dyphylline is excreted into breast milk in small amounts. The milk-to-plasma ratio is approximately 0.7. Estimated infant dose is about 1-2% of maternal weight-adjusted dose. No adverse effects reported in breastfed infants. However, monitor for signs of irritability or sleep disturbances.
Excreted into breast milk; M/P ratio unknown. Caution advised, monitor infant for adverse effects.
Pregnancy may alter the pharmacokinetics of methylxanthines due to increased plasma volume and decreased protein binding. However, dyphylline is not extensively protein-bound, so changes may be minimal. No specific dose adjustment is recommended, but monitor clinical response and toxicity. Avoid doses exceeding standard recommendations.
Increased clearance during pregnancy may require dose adjustment; monitor therapeutic levels.
Dyphylline (Lufyllin) is a xanthine bronchodilator that is not metabolized to theophylline, making it an alternative for patients who cannot tolerate theophylline. It is 2-3 times less potent than theophylline, requiring higher doses. Renal excretion is the primary elimination route; dose adjustment is needed in renal impairment. Monitor drug interactions with cimetidine, quinolones, and macrolides, though less severe than with theophylline. Use with caution in patients with peptic ulcer, hyperthyroidism, or seizure disorders. Therapeutic levels are not well-defined, but target 6-18 mcg/m L for theophylline equivalents.
ELIXICON (theophylline) requires therapeutic drug monitoring due to narrow therapeutic index of 10-20 mcg/m L. Avoid in patients with active peptic ulcer disease or seizure disorders. Use with caution in heart failure, liver disease, and elderly patients due to reduced clearance. Cigarette smoking induces metabolism, requiring dose adjustments. Common side effects include nausea, vomiting, and insomnia; toxicity presents with tachycardia, seizures, or ventricular arrhythmias.
Take this medication exactly as prescribed, do not double doses if missed.,Avoid excessive caffeine intake (coffee, tea, cola, chocolate) as it may increase side effects.,Report any signs of toxicity such as nausea, vomiting, insomnia, anxiety, or palpitations.,Do not crush or chew extended-release tablets unless instructed.,Maintain adequate hydration to help prevent side effects.,Inform your doctor if you are pregnant, breastfeeding, or have liver, kidney, or heart disease.
Take exactly as prescribed and do not change dose without consulting your doctor.,Avoid smoking and second-hand smoke as it affects how the medication works.,Limit caffeine intake (coffee, tea, chocolate, cola) as it may increase side effects.,Report symptoms of toxicity: persistent nausea, vomiting, rapid heart rate, or seizures.,Do not take this medication with other cold or asthma remedies without medical advice.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about LUFYLLIN vs ELIXICON, answered by our medical review team.
LUFYLLIN is a Xanthine Bronchodilator that works by LUFYLLIN (dyphylline) is a xanthine bronchodilator that inhibits phosphodiesterase, increasing intracellular c AMP levels, leading to relaxation of bronchial smooth muscle and suppression of airway hyperresponsiveness. It also antagonizes adenosine receptors.. ELIXICON is a Xanthine Bronchodilator that works by Theophylline is a xanthine derivative that inhibits phosphodiesterase, leading to increased intracellular cyclic AMP levels. It also acts as a nonselective adenosine receptor antagonist, resulting in bronchodilation and anti-inflammatory effects.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between LUFYLLIN and ELIXICON depend on the specific clinical indication. These are both Xanthine Bronchodilator agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of LUFYLLIN is: 200-400 mg orally 3-4 times daily, not to exceed 1600 mg/day. Also available as 200 mg/m L injection, administer 200-400 mg IM or slow IV every 6-8 hours.. The standard adult dose of ELIXICON is: 400 mg orally every 6 hours or 600 mg orally every 8 hours; extended-release: 600-1200 mg orally every 12 hours.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between LUFYLLIN and ELIXICON in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. LUFYLLIN is classified as Category C. Lufyllin (dyphylline) is a xanthine derivative bronchodilator. Animal studies have not demonstrated teratogenicity. Human data are limited; however, as a methylxanthine, risks are . ELIXICON is classified as Category C. Insufficient human data; animal studies show fetal toxicity at high doses. Avoid in first trimester unless benefit outweighs risk. Second and third trimester: use only if clearly n. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.